Connection | Reflection | Projection

 LIVE ONLINE 20 May 2020

Bio Integrates Media Centre 2021

Are you looking to expand your network, boost awareness and share your story?

This year, Bio Integrates have teamed up with Sciad, an industry specialist PR and communications agency, and Life Sciences Knowledge Hub, an online publication with a readership of 25,000 life sciences executives, to help you engage with the biotech and associated industries before, during and after the event on 20 May 2021.

Find out how we can improve your visibility by offering

1. a press release creation/distribution service
2. opportunity to submit editorials/video interviews

Scroll and click on the information below.

If you are a member of the press and would like to attend the event, please request a press pass.

 LIVE ONLINE 20 May 2021

REQUEST A PRESS PASS

Over 400 attendees live on the day

The online digital event with real-time, face to face networking

1

day

90+

speakers

400+

senior industry
executives

Our extended coverage opportunities include:

Click on the offers below to discover how you can get more exposure by being part of Bio Integrates 2021.

sciad-Logo

SCIAD Communications has a proven track record in turning complex science into compelling brand stories. By integrating brand, digital and PR we can help connect you with stakeholders to drive business development and build reputation.

sciad-Logo

Life Sciences Knowledge Hub is focused on the application of chemistry, biology and materials science to the discovery, development, formulation, manufacture and commercialization of pharmaceuticals, biotherapeutics, diagnostics and other supporting products and services within the life sciences sector.

Our other partners

Life science insights

Do you want to share your news with our community? Our Social Media reach includes 6,700 followers on Twitter and 9,000 connections on LinkedIn. Send your news to info@lsi-uk.com to be included in our communications plan.

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.

read more

Sign up for life science integrates news

Get the latest news and updates by signing up today.

By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.

Connection  |   Reflection   |   Projection

Interested in sponsorship opportunities?

Need more information?